Biomimetic DDS for overcoming intractable lung diseases by activation of macrophage functions

2015 Fiscal Year Final Research Report

• Project/Area Number: 25282146
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Biomedical engineering/Biomaterial science and engineering
• Research Institution: Nigata University of Phermacy and Applied Life Sciences
• Principal Investigator: TERADA Hiroshi 新潟薬科大学, 公私立大学の部局等, 教授 (00035544)
• Co-Investigator(Kenkyū-buntansha): MAKINO Kimiko 東京理科大学, 薬学部, 教授 (40147509) ; HIROTA Keiji 東京理科大学, 薬学部, 助教 (50516359) ; TAKEUCHI Issei 東京理科大学, 薬学部, 助教 (10734931)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: ドラッグデリバリーシステム / 結核 / 肺がん / 慢性閉塞性肺疾患 / マクロファージ / 経気管投与

Outline of Final Research Achievements

In order to overcome intractable lung diseases, such as lung cancer and lung tuberculosis, it is highly efficient to deliver their therapeutic agents directly to the lesion sites by intratracheal insufflation. The nanocomposite particles (mean particle size: 7.8μm) consisting of PLGA (poly(lactic-co-glycolic) acid) nanoparticles (mean sizes: 190 nm) containing the antitubercular agent rifampicin were prepared. These particles were distributed homogeneously in the rat and mouse lungs by the intratracheal administration by the newly developed Venturi insufflator, showing efficient antitubercular effects. In addition, the antitumor agent cyclophosphamide (CPA) increased the population of the M1 lung macrophages located around the tumor cells and showed effective antitumor activity. The lipid A analog ONO-4007 enhanced these effects of CPA.

Free Research Field

複合領域　人間医工学　生体医工学　生体材料学